ROOKMINI SINGH: Open Payments
NPI 1912475377 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$461 in 17 payments from 9 companies in 2025. Trend: 2023 $507 · 2024 $417 · 2025 $461
Food & beverage: $461
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 6 | $162 |
| SOBI, INC | 3 | $79 |
| Daiichi Sankyo Inc. | 2 | $55 |
| Azurity Pharmaceuticals, Inc. | 1 | $34 |
| GlaxoSmithKline, LLC. | 1 | $33 |
| Astellas Pharma US Inc | 1 | $31 |
| Alexion Pharmaceuticals, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| PFIZER INC. | 1 | $19 |
Products named: Fabhalta, Vonjo, SCEMBLIX, Vanflyta, DANZITEN, OJJAARA, Cresemba, ULTOMIRIS.
Industry payments across NY — which companies pay providers there.
